Overview

Study in Healthy Adults Evaluating PF-07202954

Status:
Recruiting
Trial end date:
2022-03-08
Target enrollment:
0
Participant gender:
All
Summary
The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a randomized, open label design, in Part 3 (if conducted).
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:- healthy subjects (all 3 Parts)

- evidence of steatosis on FibroScan (Part 2 only)

- BMI 17.5 to 30.5 kg/m2 (Part 1, Part 3)

- BMI 17.5 to 35.4 kg/m2 (Part 2) Exclusion Criteria:- evidence of clinically
significant disease

- subjects on chronic medications

- clinically significant, abnormal laboratory results, vital signs, or cardiac
conduction abnormalities

- contraindication to MRI (Part 2, only)